XBiotech Inc. (NASDAQ:XBIT) Short Interest Up 452.0% in July

Key Points

• XBiotech Inc. experienced a significant increase in short interest, rising by 452.0% in July, with a total of 516,100 shares short as of July 15th.
• The company's stock is currently priced at $2.85, with a market cap of approximately $86.90 million and a 52-week trading range between $2.50 and $8.32.
• Institutional investors hold 55.70% of XBiotech's stock, with recent increases in holdings from firms such as Northern Trust Corp and Charles Schwab Investment Management.

XBiotech Inc. (NASDAQ:XBIT - Get Free Report) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 516,100 shares, agrowthof452.0% from the June 30th total of 93,500 shares. Approximately2.7% of the company's shares are short sold. Based on an average trading volume of 93,700 shares, the short-interest ratio is presently 5.5 days. Based on an average trading volume of 93,700 shares, the short-interest ratio is presently 5.5 days. Approximately2.7% of the company's shares are short sold.

XBiotech Stock Performance

NASDAQ XBIT opened at $2.85 on Friday. The firm's 50 day moving average price is $2.88 and its 200-day moving average price is $3.09. XBiotech has a 52-week low of $2.50 and a 52-week high of $8.32. The company has a market cap of $86.90 million, a PE ratio of -2.21 and a beta of 0.97.

XBiotech (NASDAQ:XBIT - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On XBiotech

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Northern Trust Corp boosted its stake in shares of XBiotech by 15.2% during the fourth quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company's stock valued at $835,000 after purchasing an additional 27,909 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of XBiotech by 15.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 67,355 shares of the biopharmaceutical company's stock valued at $218,000 after purchasing an additional 8,918 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of XBiotech during the second quarter valued at approximately $142,000. Deutsche Bank AG bought a new position in shares of XBiotech during the fourth quarter valued at approximately $120,000. Finally, Barclays PLC boosted its stake in shares of XBiotech by 13.9% during the fourth quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company's stock valued at $119,000 after purchasing an additional 3,661 shares in the last quarter. 55.70% of the stock is currently owned by institutional investors.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.